Boston Scientific announces positive FRACTURE trial results for SEISMIQ catheter
The SEISMIQ 4CE catheter met primary safety and effectiveness endpoints for treating severe coronary artery disease.
See the latest news and media coverage for Boston Scientific. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global medical device manufacturer
bostonscientific.comLast updated
In short: Boston Scientific reported strong revenue growth, made a $1.5 billion investment in MiRus, and achieved success in several cardiovascular trials.
The SEISMIQ 4CE catheter met primary safety and effectiveness endpoints for treating severe coronary artery disease.
The ASR with JPMorgan will repurchase 80% of the $2 billion upfront, settled by June 2026, accretive to EPS.
The investment includes an exclusive option to acquire a novel TAVR system using rhenium alloy.
Data from AVANT GUARD trial shows FARAPULSE PFA superiority over anti-arrhythmic drugs. WATCHMAN LAAC devices demonstrate safety and effectiveness in multiple studies.
The superalloy molybdenum-rhenium (MoRe) is a big part of why Boston Scientific is betting big on the MiRus Siegel TAVR heart implant.
Morningstar is an investment research company offering mutual fund, ETF, and stock analysis, ratings, and data, and portfolio tools. Discover actionable insights today.
Boston Scientific Corporation (NYSE:BSX) is one of the most promising healthcare stocks according to...
Stryker trades at $310.75 today, up 3.19%. Legal win clears path for new device launch and stronger market presence.
Track Boston Scientific and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Boston Scientific and other trending companies.